Hennekens C H, Jonas M A, Buring J E
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Arch Intern Med. 1994 Jan 10;154(1):37-9.
Acute myocardial infarction (MI) remains far and away the leading cause of death in the United States, and is responsible for approximately 500,000 annual fatalities. However, mortality due to MI has declined substantially in recent decades, owing to advances in treatment as well as prevention. Low-dose aspirin as well as thrombolytic therapy given during acute evolving MI each decrease mortality by about one quarter. Both therapies remain underutilized in the United States. Aspirin can be given to virtually all patients, has a far more favorable safety profile than thrombolysis, and confers a comparable benefit at a small fraction of the cost of thrombolytic agents. The more widespread use of aspirin in acute MI is one of the most important and timely clinical challenges in the United States.
急性心肌梗死（MI）仍然是美国远远领先的首要死因，每年约有50万人因此死亡。然而，由于治疗和预防方面的进展，近几十年来因心肌梗死导致的死亡率已大幅下降。在急性进展期心肌梗死期间给予低剂量阿司匹林以及溶栓治疗，均可使死亡率降低约四分之一。在美国，这两种疗法的使用仍然不足。阿司匹林几乎可以用于所有患者，其安全性远优于溶栓治疗，并且以溶栓药物成本的一小部分就能带来相当的益处。在美国，更广泛地使用阿司匹林治疗急性心肌梗死是最重要且紧迫的临床挑战之一。
